MKKGY News and Press, Merck KGaA ADR From 05/26/23

2023-05-26 14:01:57 ET Oncolytics Biotech ( NASDAQ: ONCY ) shed ~16% on Friday after announcing results from its Phase 2 trial for experimental therapy pelareorep as a combination regimen in patients with a certain type of breast cancer. Results shared ahead of a presentatio...

2023-05-25 19:36:30 ET Summary It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche Holding AG reported positive results reported from ...

2023-05-17 05:06:24 ET Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial by reducing brain lesions in adults with relapsing forms of multiple sclerosis (RMS). The 12-week mid-stage study, dubbed FENopta...

2023-05-16 01:29:25 ET Summary GSK's operating income margin in Q1 2023 was 29.35%, showing an increase in the previous quarter and the last year. Vaccine sales were $2,493 million in Q1 2023, up 11.9% year-over-year, mainly due to Fluarix and FluLaval, which regulators approved t...

2023-05-11 13:41:03 ET Merck KGaA (MKGAF) Q1 2023 Earnings Conference Call May 11, 2023 08:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chair of the Executive Board and Chief Executive Officer Marcus Kuhnert - Chi...

2023-04-26 13:15:56 ET Summary Initiation of phase 3 study using PDS0101 in combination with Keytruda for the treatment of patients with unresectable, recurrent/metastatic Human Papillomavirus positive head and neck cancer expected Q4 of 2023. It is said that the global head and n...

2023-04-18 11:30:00 ET Summary Merck KGaA (not to be confused with the US-based Merck) is a German company in the life sciences and healthcare sector. The balance sheet is looking very healthy again focusing on the reduction of the net debt. This means Merck is in a position a...

2023-03-29 15:05:26 ET Summary This portfolio uses historical performance and qualitative business traits to determine low-risk assets. These assets are leading their class and represent sectors that offer lower volatility. Backtesting proves that the constituents outperform t...

2023-03-21 12:51:16 ET Vaccinex ( NASDAQ: VCNX ) said a phase 1b/2 trial of pepinemab in combination with avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma (PDAC) has started. The main goal of the trial is to investiga...

The following slide deck was published by MERCK Kommanditgesellschaft auf Aktien in conjunction with their 2022 Q4 earnings call. For further details see: MERCK Kommanditgesellschaft auf Aktien 2022 Q4 - Results - Earnings Call Presentation